Takeda gets a potential blockbuster bonus on $5B Ariad deal with FDA’s approval of brigatinib
Takeda is getting a big bonus from the FDA today for its $5.2 billion buyout of Ariad. The pharma company acquired the late-stage cancer drug brigatinib in the acquisition back in January, and now the FDA has approved it for ALK-positive cases of non-small cell lung cancer.
Takeda can now set out to realize its projections of $1 billion-plus in annual sales for brigatinib — which will be marketed as Alunbrig — which are significantly more aggressive than most analysts, who have been predicting $500 million to $800 million in sales.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
